Frontage Laboratories Appoints Carlos Orantes As Chief Operating Officer

Frontage Laboratories Appoints Carlos Orantes As Chief Operating Officer

Exton, P.A., (February 18, 2014) – Frontage Laboratories today announced that Carlos Orantes has been appointed Chief Operating Officer. A twenty-year veteran of contract research and life science industries, he will lead Frontage's US operations, which comprise a 60,000 square foot laboratory for bioanalysis and DMPK functions, an 88-bed clinical research unit and a portfolio of CMC services, including product development, analytical testing and CTM manufacturing.

"Mr. Orantes brings an impressive record of designing and leading successful growth strategies for companies that are large and small, both private and publicly-held entities," said Dr. Song Li, Chairman and CEO. "Our goal is to expand our service offerings to meet shifting industry needs, and make it easier for customers to do business with us by bringing technical guidance, excellent customer service along with new services to solve the needs of our customers. I'm confident that Frontage and our customers will significantly benefit from his business experience driving strategic initiatives as the company enters its next phase of growth."

"Frontage has a strong commitment to exceptional science, and I am excited to have the opportunity to lead efforts as we continue to build offerings and customer support that are both integrated and world-class," said Mr. Orantes.

Mr. Orantes previously served as President and CEO of AVANZA Laboratories LLC. There, he developed the company's business strategy, and led activities related to the company's asset purchase in 2012 by the Smithers Group.

Prior to AVANZA, Mr. Orantes was General Manager and Vice President for Bridge Laboratories, a toxicology and immunology testing laboratory where he held management responsibility for US operations. Earlier career positions included 10 years of operational, quality assurance, process improvement and management roles of increasing responsibility at Covance.

Mr. Orantes earned a master's of business administration degree from Old Dominion University, and a bachelor of science degree in biology from George Washington University. He is Six Sigma Black Belt certified from the Six Sigma Academy.

About Frontage

Frontage helps biopharmaceutical organizations advance their research and development efforts with full service offerings– including bioanalysis, preclinical and clinical studies, analytical testing and product development support– spanning discovery stages through late-stage clinical trials. The company also provides turnkey product development, bioequivalence and analytical services to generic and consumer health pharmaceutical companies to support Abbreviated NDA and 505.b.2 application submissions.

With a 12-year history of bioanalytical, clinical research and CMC operations, eight state-of-the art research facilities and more than 320 professionals in the US and China, Frontage has enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through clinical development and commercial launch in global markets. For more information, visit

Katherine Cloninger
Director, Marketing
[email protected]